Items where Funder is MRC (Medical Research Council) Exceptions.

FAISAL AL-TERKAIT

Colomban, O, Tod, M, Peron, J et al. (6 more authors) (2020) Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectrum, 4 (3). pkaa026. pkaa026-. ISSN 1475-4029

You, B, Tod, M, Leary, A et al. (12 more authors) (2020) Preponderant impact of the chemosensitivity assessed by the modeled CA-125 kinetic parameter KELIM on the success of the first line treatment: Pooled analysis of AGO-OVAR 7, AGO-OVAR 9 and ICON7 trials--a GINECO-GINEGEPS study. In: 51st Annual Meeting of the Society of Gynecologic Oncology, 28-31 Mar 2020, Toronto, Canada.

Hall, M, Bertelli, G, Li, L et al. (7 more authors) (2020) Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. International Journal of Gynecological Cancer, 30 (2). pp. 213-220. ISSN 1048-891X

Ray-Coquard, I, Hatcher, H, Bompas, E et al. (16 more authors) (2020) A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). International Journal of Gynecological Cancer. ISSN 1048-891X

UK JG 08-102015 SM

Ray-Coquard, I, Hatcher, H, Bompas, E et al. (16 more authors) (2020) A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). International Journal of Gynecological Cancer. ISSN 1048-891X